Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
FBLG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.76 - $13.59
Previous CloseN/A
Volume56.64K
Average Volume (3M)199.10K
Market Cap
$48.68M
Enterprise Value$64.60M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding37,735,300
10 Day Avg. Volume320,752
30 Day Avg. Volume199,096
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-147.81
Enterprise Value/Ebitda-3.75
Forecast
1Y Price Target
$12.00Price Target Upside830.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
FibroBiologics, Inc. News
See All FBLG News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe planned Phase 1/2 trial in Australia for DFU patients is anticipated to be completed by the end of 2025, which is viewed as a relatively near-term catalyst for supportive validation of fibroblast benefit in diabetic wound healing.
Market OpportunityChronic wound care represents a sizable market with $28B in healthcare spending, providing a significant opportunity for FibroBiologics.
Therapy AdvancementFibroblast therapy could provide improved wound healing quality with superior and timely wound size reduction based on preclinical development.
Bears Say
Financial PerformanceFibrobiologics reported 3Q24 results with an operating loss of ($3.4M) and cash of $7.8M.
Funding ConcernsThe company is expected to be funded into mid-2025.
---
Ownership Overview
15.68% Insiders
4.21% Mutual Funds
0.29% Other Institutional Investors
73.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.76 and its highest was $13.59 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $48.68M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.072 by $0.062.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 37,735,300 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.072. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at 0.
---
FibroBiologics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (830.23% Upside)
$12.00 (830.23% Upside)
Blogger Sentiment
Bullish
FBLG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.80%
12-Months-Change
Fundamentals
Return on Equity
-559.73%
Trailing 12-Months
Asset Growth
87.14%
Trailing 12-Months
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. (FBLG) is a biotechnology company focused on developing and commercializing advanced cellular therapies that leverage fibroblast cells for regenerative medicine. The company operates in the biotechnology sector, emphasizing the development of therapies for various medical conditions, including chronic diseases and degenerative disorders. FibroBiologics aims to harness the therapeutic potential of fibroblasts to address unmet medical needs and improve patient outcomes.
---
FBLG Stock 12 Month Forecast
Average Price Target
$12.00
▲(830.23% Upside)
Technical Analysis
Dyadic International
―
Forte Biosciences
―
Reviva Pharmaceuticals Holdings
―
Connect Biopharma Holdings
―
OKYO Pharma Limited Sponsored ADR
―
Best Analysts Covering FBLG
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-24.10%
reiterated a buy rating 27 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -24.10% per trade.
---